Abstract The ErbB receptor tyrosine kinase family has often been associated with increased growth of breast epithelial cells, as well as malignant transformation and progression. In contrast, ErbB4/HER4 exhibits unique attributes from a two step proteolytic cleavage which releases an 80 kilodalton, nuclear localizing, tyrosine kinase to a signal transduction mechanism that slows growth and stimulates differentiation of breast cells. This review provides an overview of ErbB4/HER4 in growth and differentiation of the mammary epithelium, including its physiologic role in development, the contrasting growth inhibition/tumor suppression and growth acceleration of distinct ErbB4/HER4 isoforms and a description of the unique cell cycle regulated pattern of nuclear HER4 ubiquitination and destruction.
Almost fifty years ago Stanley Cohen, using a near heroic bioassay, purified a polypeptide from mouse salivary glands whose activity resulted in premature eyelid opening and tooth eruption in neonatal mice [1] . Cohen's isolation of "tooth-lid" factor (quickly renamed epidermal growth factor, or EGF) initiated research in growth factors and their receptors in the modern sense. Biochemical purification, peptide sequencing and cDNA cloning identified the epidermal growth factor receptor (EGFR) as a 170 kDa transmembrane protein [2] ; this receptor was the first ligand-activated tyrosine kinase described [3] . The ligands defined by homology to EGF has expanded to include at least ten growth factors across two gene families, which bind to a family of four receptor tyrosine kinases (RTKs) that includes the EGFR [4] [5] [6] [7] [8] [9] . These families of ligands and receptors have been firmly linked to proliferative signaling and oncogenesis. The association began with early studies of growth regulation and identification of EGFR family member expression or overexpression in human malignancies, but the link was permanently forged by a surprise arising from the cDNA sequence of the first receptor tyrosine kinase cloned. The EGFR (also known as HER1 or ErbB1) cytoplasmic domain was found to be the human ortholog of the chicken retroviral oncogene, v-erbB. This established this receptor tyrosine kinase's oncogenic potential and identified the EGFR as one of the early proto-oncogenes [2] Isolation of a mutated receptor tyrosine kinase in rat tumors, the neu oncogene, and molecular studies of breast cancer cells led to the identification of a second EGFR/HER2 family member, HER2/ ErbB2/Neu [10, 11] . Soon labs identified the remaining EGFR family members, HER3/ErbB3 [12, 13] and HER4/ ErbB4 [14] . Over the years, multiple investigators (see review [8, 9, 15, 16] ) have linked the EGFR family to the causation or progression of breast cancer and other epithelial malignancies. Moreover the overexpression is often linked to poor patient outcomes or advanced tumor state. Activation or overexpression of EGFR or HER2/ErbB2 in breast, colon and other tumors has proven to be therapeutically relevant. Small molecule inhibitors of EGFR and HER2/ErbB2 and monoclonal antibodies-targeting EGFR and HER2/ErbB2 have been successfully developed and used to treat human patients with a substantial saving of lives [15, [17] [18] [19] . For all of these reasons the EGF receptor family is firmly linked to proliferative, prosurvival and oncogenic events.
The first forty years of research into the EGF family were primarily aimed at understanding how the majority of these growth factors stimulate proliferation and survival of epithelial cells, promote tumor formation, and enhance tumor malignancy. However in Drosophila and C. elegans, a single EGF receptor gene is also linked to differentiation signaling [20] and more recent evidence in mammals indicates that one of the ErbB receptors, HER4/ErbB4, initiates anti-proliferative and pro-differentiation signals. These "non-traditional" actions of ErbB4/HER4 will be the subject of this review.
The ErbB Receptors and Their Ligands
In addition to EGF, other ErbB agonists have been identified that share homology to EGF in a 50-amino acid region known as the EGF-like domain [5, 21] . Of these, EGF, transforming growth factor-α and amphiregulin bind exclusively to EGFR/HER1. Betacellulin, epiregulin, and heparin binding EGF-like factor (HB-EGF) bind to both EGFR/HER1 and HER4/ErbB4, whereas heregulin (neuregulin-1) and neuregulin-2 bind to both ErbB3/HER3 and ErbB4/HER4 [5, [22] [23] [24] . Neuregulin-3 and -4 bind exclusively to ErbB4/HER4. Finally, activities of the ErbB receptors are modified by non-conventional agonists (decorin, tomoregulin, epigen, MUC4, or Cripto-1 [25] [26] [27] ). The growth factors that bind to the EGF receptor family members are often expressed in human tumors. Most translational data correlate ligand expression with tumor progression or metastasis in human cancers.
The family's complexity extends beyond these four receptors and ten potential ligands because the various receptors can either homodimerize or heterodimerize in a ligand-dependent way. EGFR and HER4/ErbB4 can homodimerize when bound to ligands, or heterodimerize with any of the other ErbB receptors, with ErbB2/HER2 being the preferred heterodimeric partner. ErbB2/HER2 and ErbB3/HER3 each require heterodimerization in order to transduce signals, because ErbB3/HER3 does not have an intrinsic kinase, while ErbB2/HER2 is not bound by any known ligand [4-6, 21, 28] .
There is perhaps no better example of the biologic complexity of the system and its dependence upon receptor expression and cellular context than the initial studies describing the identification of heregulin/neuregulin-1 [29, 30] . One group purified heregulin on the basis of its ability to increase growth of certain cancer cells. Another group isolated NEU differentiation factor based on its anti-proliferative effect in cancer cells. Both factors were encoded by the same gene, underscoring the bidirectional signaling possibility of the same ligand depending upon the cellular context and ErbB family members present.
HER4/ErbB4: Positive Breast Cancer Prognosis, Differentiation, and Growth Inhibitory Signaling
While increased expression and/or activity of EGFR, HER2, and HER3 have been described in human breast cancers, overexpression of HER4/ErbB4 in breast cancer rarely occurs. In fact, HER4/ErbB4 expression is detectable in less than half of breast cancers depending on the technique used [31] [32] [33] [34] [35] and correlates in general with increased differentiation and more positive prognostic indicators, consistent with the hypothesis that HER4/ErbB4 signaling promotes differentiation and growth inhibition of breast cells [32, 33, [35] [36] [37] [38] [39] [40] . HER4 expression also predicts a better outcome in patients with carcinoma in situ [41] .
Initial studies with several breast cancer cell lines demonstrated heregulin-dependent growth inhibition. For example, in the work that identified and sequenced HER4/ ErbB4, Plowman and colleagues demonstrated that activation of HER4/ErbB4 with heregulin slowed growth and produced a more differentiated epithelial phenotype [14] . The initial studies in our lab showed that heregulin slowed the growth of SUM44 breast cancer-derived cells, and induced their morphologic differentiation, including an increase in lipid droplets [42] . HB-EGF also produced this growth inhibitory phenotype, ruling out the role of HER2-HER3 heterodimers in this growth inhibitory response, since HB-EGF is specific for EGFR and HER4/ErbB4 [42] . Intracellular antibody-mediated depletion of cell surface ErbB2/HER2 expression in SUM44 cells did not affect heregulin-mediated growth inhibition, demonstrating that HER4-HER2 heterodimers were not required for growth inhibition in response to heregulin. Because SUM44 cells lack EGFR expression, this suggested that HER4/ErbB4 homodimers inhibited SUM44 cell growth in response to HB-EGF and to HRG. It was also found that exogenous HER4/ErbB4 expression in a HER4-negative breast cancer cell line (SUM102) could confer heregulin-mediated growth inhibition to these otherwise unresponsive cells [42] .
HER4/ErbB4 Isoforms, A New Paradigm
Sequencing of HER4/ErbB4 cDNAs revealed that HER4/ ErbB4 mRNA could be alternatively spliced in two areas-the first in the extracellular juxtamembrane region (JMa or JMb) [43, 44] ; and the second in the C-terminus distal to the tyrosine kinase domain (Cyt1 and Cyt2) [45, 46] . The JMa isoform introduces an extracellular proteolytic site which is subject to cleavage by a metalloprotease known as tumor necrosis factor-alpha converting enzyme (TACE) [47] . ErbB4/ HER4 cleavage by TACE occurs upon ligand-activation of ErbB4/HER4, and is dependent upon ErbB4/HER4 kinase activity [48] . Metalloprotease-mediated cleavage is seen in other receptor tyrosine kinases. The JMb isoform lacks the TACE cleavage site, and therefore cannot be cleaved.
The importance of ligand-dependent, TACE-mediated cleavage of ErbB4/HER4 became apparent when it was further shown that the JMa isoform, once cleaved by TACE, could undergo a second intramembrane cleavage via a γ-secretase-like activity similar to the genesis of Notch intracellular signaling [49, 50] . The secondary cleavage of ErbB4/HER4 releases into the cytoplasm the soluble, 80 kDa intracellular domain of ErbB4, referred to herein as s80 HER4 . Mutation of the critical, γ-secretase cleavage site, the last valine in the transmembrane domain, inhibits the liberation of s80 HER4 into the cytosol, without impairing the formation of the membrane-tethered m80 isoform [51, 52] .
HER4/ERBB4 Localizes to the Nucleus
Once liberated into the cytoplasm, s80 HER4 exhibits nuclear localization. Interestingly, many HER4/ErbB4-positive breast cancers exhibit nuclear HER4/ErbB4. Normal human and mouse mammary tissue, endometrial cancers and normal sensory epithelium all display nuclear HER4/ErbB4 [40, 53, 54] . Introduction of exogenous GFP-s80 HER4 by transfection or retroviral infection into breast cancer or mouse mammary cell lines result in the nuclear localization of GFP-s80 HER4 ( [55] and Fig. 1 ). Nuclear-cytoplasmic translocation of s80 HER4 may have been predicted based on three putative nuclear localization sequences within the intracellular domain of ErbB4/HER4 [49] , one of which has been shown to be required for nuclear localization of the ErbB4 intracellular domain. There are also three putative nuclear export sequences [49] , and a D-box motif, an amino acid sequence present in proteins that are targeted by the anaphasepromoting complex, a nuclear E3-ubiquitin ligase [56] .
The function of s80 HER4 in the nucleus, or how its active tyrosine kinase affects nuclear functions is not yet fully understood. It is known, however, that kinase activity of s80 HER4 is required for its nuclear localization, since kinaseinactive s80 HER4 is not found in the nucleus [52, 55] .
Treatment of cells expressing s80
HER4 with the pan-ErbB small molecule inhibitor GW572016 dramatically reduced the nuclear accumulation of GFP-s80 HER4 , resulting in its cytoplasmic accumulation ( [55] , Fig. 1 ), confirming that kinase activity of s80 HER4 is required for its nuclear localization.
HER4/ErbB4 Alone Can Signal for Growth Inhibition
Guided by these findings and the fact that SUM44 breast cell line expressed the JMa isoform, we examined the role of this unique aspect of HER4/ErbB4 biology. First we used a pan EGF receptor family small molecule tyrosine kinase inhibitor, GW572016, to inhibit the HER4/ErbB4 tyrosine kinase activation, which is necessary for ligandinduced HER4/ErbB4 cleavage and release of s80 HER4 . HER4/ErbB4 tyrosine kinase inhibition blocked the growth inhibitory signal [55] . Next we inhibited s80 HER4 production by protelysis using a small molecule γ-secretase inhibitor [55] . This too blocked the HER4/ErbB4 antiproliferative signal; similar experiments were performed by Carpenter and co-workers [49] . Lastly we constructed SUM44 cells stably expressing GFP-s80 HER4 , the GFP-CT HER4 (GFP tagged HER4 C-terminus without the tyrosine kinase domain) or GFP alone. GFP-s80 HER4 translocated to the nucleus and inhibited cell growth. Neither GFP nor GFP-CT HER4 had this effect. We have repeated these latter experiments with similar results in multiple breast cell lines including malignant MDA-MB-453 and SUM102 cells as well as non-malignant, MCF-10A, and HC11 (a cell line cultured from pregnant mouse mammary cells). Thus s80 HER4 was both necessary and sufficient for HER4-dependent growth inhibition. These results and the majority of clinical translational data from human breast cancer series suggest that HER4/ErbB4 can have tumor suppressor-like activities.
Other studies have demonstrated that HER4/ErbB4 activity can induce apoptosis in breast cancer-derived cells [57] . This work demonstrated mitochondrial accumulation of ErbB4, and interaction between the pro-apoptotic protein BAK and the BH3-like domain within the HER4/ErbB4 intracellular domain. The pro-apoptotic activity of HER4/ ErbB4 was counteracted by its interaction with the antiapoptotic protein Bcl2. These results indicate that ligandinduced HER4/ErbB4 activity may result in death of breast cancer cells, suggesting yet another mechanism by which HER4/ErbB4 limits tumor growth and correlates with a positive prognosis for patients with breast cancer.
ErbB4/HER4 in Embryonic Mammary Bud Specification
Development and maturation of the mammary epithelium requires precise coordination of cellular processes, including cell proliferation, differentiation, and survival. Aberrations in the control of these developmental mechanisms are potentially oncogenic (reviewed in [58] ). Normal programming signals involve factors that drive proliferation of the breast epithelium, as well as signals that restrain proliferation. In addition, processes must allow for removal of unneeded cells in a timely fashion. Because the breast epithelium is capable of multiple cycles of robust expansion, for example during puberty and pregnancy, control of these processes is paramount to allow multiple rounds of lactation and for the prevention of tumor formation.
During embryogenesis, mammary gland formation requires an exchange of signals between epithelia and mesenchyme [59] . Signaling molecules from the mesenchyme induce the directional migration, but not proliferation per se, of ectodermally-derived epidermal cells to form the embryonic mammary bud. Within this structure, a population of mammary stem cells exists that will subsequently proliferate to form an arborized epithelium filling the mammary fatpad, and which is capable of milk production [59] .
Neuregulin3 (Nrg3), a ligand that binds to ErbB4/HER4, regulates mammary bud specification in mice. Expression of Nrg3 and ErbB4/HER4 in the presumptive mammary region around the future bud site directly precedes the morphological appearance of mammary buds and of bud epithelial markers. Nrg3-soaked beads induced ectopic mammary bud formation and the expression of LEF1, the earliest known mammary bud marker [60] . Furthermore, immunohistochemical localization of Nrg1-4 and ErbB4
A.
B. occurred at stages prior to morphological appearance of the mammary bud and/or through later embryonic stages of mammary organogenesis [60] . These data suggest that ErbB4/HER4 signaling may directly contribute to inductive events in mammary gland specification.
ErbB4/HER4 in Lactational Differentiation of the Mammary Gland
Aside from specification and formation of the rudimentary mammary epithelium, the majority of mammary gland development occurs postnatal. Prior to puberty, the rudimentary mammary epithelium invaginates from the nipple in the proximal tip of the mammary fat pad. As puberty proceeds, the ductal epithelium proliferates, lengthening and invading the mammary fat pad in a proximal-to-distal direction, until the entire fat pad is permeated with epithelium at the end of puberty, and ductal proliferation ceases. Terminal end buds (TEBs), the club-shaped structures at the distal aspect of the mammary epithelium, represent the most proliferative region of the pubertal mammary gland [59] . Extensive developmental studies in the mouse demonstrate that EGFR/HER1, ErbB2/HER2, and ErbB3/HER3 each contribute to proliferation and/or survival of MECs, especially during puberty [61] . In the developing mouse mammary gland, expression and activity of ErbB1-3 appear to be highest during phases of epithelial proliferation, such as puberty and pregnancy. Overexpression of ligands that activate EGFR/HER1 signaling results in increased proliferation. For example, increased expression of TGFα in MMTV-TGFα mice results in formation of hyperplastic alveolar nodules (HANs), due to increased proliferation of the mammary epithelium. Similarly, overexpression of an ErbB receptor may increase proliferation of the mammary epithelium [6, 7, 61] . For example, MMTV-neu mice, which overexpress c-Neu (the rat homolog of ErbB2/ HER2) in the mammary epithelium, develop hyperplastic glands and metastatic focal carcinomas [6] . Although less is known regarding ErbB3/HER3 in growth and development of the mammary epithelium, recent evidence suggests that loss ErbB3 expression in mice results in impaired proliferation of the mammary epithelium [62] , while ErbB3/HER3 is often co-expressed with ErbB2/HER2 in breast cancers, correlating with a poor prognosis, and generating the hypothesis that HER2-HER3 heterodimers may function to simultaneously drive breast epithelial cell proliferation and survival. These data support the proposed role of these members of the ErbB family as stimulators of cellular proliferation in the mammary epithelium.
ErbB4/HER4 signaling is unique among ErbB receptors in the mammary epithelium, in that it is required for the differentiation of mouse mammary epithelial cells during pregnancy and promotes differentiation of murine and human mammary epithelial cells in cell culture, but is not required to drive proliferation of the mammary epithelium. The pituitary peptide hormone prolactin (PRL) controls the differentiation of mammary epithelial cells (MECs) during pregnancy, along with other peptide hormones, steroid hormones, and local growth factors. Upon PRL binding to its receptor, PRLR, expressed on MECs, the intracellular tyrosine kinase Janus kinase 2 (JAK2) is stably recruited to the receptor complex. Tyrosine kinase activation of JAK2 results in tyrosine phosphorylation of PRLR, allowing its association with signal transducer and transcriptional activator 5a (STAT5a) in an SH2-dependent manner. The subsequent phosphorylation of STAT5a by JAK2 triggers activation and nuclear translocation of STAT5a, where STAT5a activates transcription of target genes, including milk protein genes like β-casein [63] [64] [65] [66] .
Mouse models examining the loss of PRL, PRLR, JAK2, and STAT5a in the mammary epithelium all exhibit an overlapping phenotype of impaired expansion and terminal differentiation of the mammary epithelium during pregnancy, and impaired survival of differentiated mammary epithelial cells, together causing insufficient lactation to support nursing pups [64] [65] [66] . Because PRL, PRLR, and JAK2 signals ultimately funnel down to STAT5a, these data strongly suggest that STAT5a mediates indispensable, biologically relevant functions of PRL signaling in normal mammary epithelial cells.
Studies of normal mammary tissue of humans, mice, or rats agree that ErbB4/HER4 expression and activity (measured by tyrosine phosphorylation) is lowest during phases of epithelial cell proliferation (puberty and early pregnancy) and highest during phases of differentiation (late pregnancy and early lactation) [61] . This suggests that ErbB4/HER4 may direct differentiation and growth inhibition of the mammary epithelium. In agreement with this expression data, mammary glands from mice that lack ErbB4 activity by multiple genetic strategies each have lactation defects due an impaired program of differentiation, measured by a decrease in the expression of milk proteins (β-casein and whey acidic protein) and a decrease in activity of the transcription factor STAT5a [67] [68] [69] . The phenotype of ErbB4-deficient mammary glands is strikingly similar to what is observed in mammary-specific models of JAK2 [70] and STAT5a-deficiency [71] . Similarly, impaired ErbB4 association with HB-EGF causes a lactation deficiency reminiscent of the phenotype of mammary glands lacking ErbB4, STAT5a, or JAK2 [72] . Furthermore, the ErbB3-ErbB4 ligand Nrg1/HRG induces differentiation of mammary organ cultures and of mammary glands in vivo in a HER2-independent fashion, while disruption of Nrg1/HRG expression impairs late stage differentiation of the mammary epithelium [73] . These data suggest that ErbB4/HER4 directs differentiation of the mammary epithelium.
ErbB4/HER4 and s80 HER4 Differentiate Normal Mammary Epithelial Cells in Culture
Because ErbB4-deficient mammary epithelial cells fail to demonstrate activation of STAT5a, even in the context of an intact PRL-PRLR-JAK2-STAT5a signaling axis, it was determined that ErbB4 must be an obligate mediator of STAT5a activation in the mammary gland. The mechanism underlying this observation has been elusive, but may relate to the unique proteolytic processing of ErbB4/HER4 following ligand binding that results in liberation of the soluble intracellular domain, s80
HER4 . HC11 cells, MECs derived from a mouse at midpregnancy, reliably mimic many of the molecular steps of lactogenic differentiation in culture, including the transcription of the milk protein β-casein, in a STAT5a-dependent manner. Using HC11 cells, it was shown that STAT5a is activated in response to ligand-stimulated ErbB4/HER4 by HRG or HB-EGF, but not in cells expressing kinase-dead ErbB4/HER4. These results suggest that kinase activity of ErbB4/HER4 is required for ErbB4/HER4-mediated STAT5a activation. HC11 cells cultured in three-dimensional Matrigel were induced to form acini, consisting of an organized single epithelial layer surrounding a lumen when cultured in the presence of PRL or ErbB4/HER4 ligands, but not when cultured in the presence of EGF (an EGFR/HER1-specific ligand), nor when cultured in the absence of ligands [52] .
Additional studies suggest that formation of s80 HER4 is required for these aspects of ErbB4/HER4-mediated differentiation [52] . Overexpression of an ErbB4/HER4 variant encoding a point mutation in the γ-secretase cleavage site impaired liberation of s80 HER4 from full-length ErbB4/ HER4, while also inhibiting nuclear translocation of STAT5a in response to HB-EGF. Overexpression of the γ-secretase site mutant of ErbB4/HER4 also impaired PRLmediated activation of STAT5A activity in response to PRL, suggesting that formation of s80 HER4 is a critical step in ErbB4/HER4-mediated activation of STAT5a and thus in lactogenic differentiation. Conversely, HC11 cells expressing exogenous s80
HER4 from a cDNA construct exhibited STAT5a activity even in the absence of PRL, and exhibited rudimentary lumen formation in the absence of PRL. These data suggest that s80 HER4 formation is sufficient for many aspects of structural and lactogenic differentiation of MECs. It has also been demonstrated that STAT5a interacts directly with the intracellular domain of ErbB4/HER4 in cultured cells. Mutations in the ErbB4 intracellular domain that impair nuclear localization of ErbB4 also impaired nuclear localization of STAT5a [74] . Because STAT5a lacks its own canonical nuclear localization sequences, these observations support the hypothesis that ErbB4/HER4 chaperones STAT5a into the nucleus.
It is also possible that nuclear ErbB4/HER4/ERBB4 influences STAT5a-mediated transcriptional activity in a more direct manner. In support of this idea, ErbB4/HER4 was detected in association with chromatin-bound STAT5a, specifically on sequences located within the β-casein promoter [74] . The idea that nuclear ErbB4/HER4 may regulate the activity of transcriptional complexes is not without precedent. ErbB4/HER4 has been shown to form a complex with transcriptional co-repressors NCoR and TAB2 in vivo. The tripartite complex is translocated to the nucleus in a manner dependent upon s80 HER4 and its tyrosine kinase. This complex acts as a transcriptional corepressor in the developing mouse astrocyte, specifically localized to the GFAP promoter regions [75] .
HER4/ErbB4 Activity Inhibits Growth of Mammary Epithelial Cells via a G2/M Delay Involving BRCA1
In addition to promoting differentiation of MECs, it has been observed that ErbB4/HER4 activity may decrease their growth. Examination of a panel of human breast cancer-derived cell lines demonstrated that ErbB4/HER4-positive cells were growth inhibited by the ErbB3/ErbB4 ligand heregulin/Nrg1. In contrast, ErbB4/HER4-negative cells displayed increased growth in the presence of heregulin/Nrg1. Heregulin increased the proportion of ErbB4/ HER4-positive breast cancer and other cancer cells in the G2/M phase of the cell cycle, but not ErbB4/HER4-negative cells [56, 76] . For example, Fig. 2 demonstrates the increase in G2/M phase cells brought about in the HER4 positive SUM44 and BT-474 breast cancer cell lines.
ErbB4-positive cells display a heregulin-mediated increase in the expression of the G2/M checkpoint protein BRCA1 in a HER4/ErbB4-dependent, ErbB2/HER2-independent manner [76] , suggesting that perhaps ErbB4/HER4 homodimers were mediating this process, as opposed to HER4-HER2 or HER3-HER2 heterodimers. In a sample of human breast cancers, ErbB4/HER4 mRNA expression showed a positive correlation with BRCA1 mRNA expression [76] . Furthermore, BRCA1 activity is required for heregulin-mediated growth inhibition of breast cells, as knock-down of BRCA1 expression inhibits heregulinmediated growth inhibition of breast cancer cells, and mammary epithelial cells from a conditional mammaryspecific BRCA1 knock-out model were insensitive to heregulin-induced growth inhibition [76] . These results are consistent with a hypothesis that ErbB4/HER4 impairs growth by inducing a G2/M checkpoint, perhaps one involving BRCA1. The signaling mechanism by which ErbB4/HER4 induces growth inhibition or regulates expression of BRCA1 is currently unknown, however all of our evidence supports the concept that production of s80 HER4 is necessary. Additionally, our data cited earlier that expression of exogenous s80 HER4 in a panel of breast cancer cells or into "normal" human and mouse mammary epithelial cells (MCF-10A and HC11, respectively) conferred growth inhibition indicates that s80 HER4 is sufficient for growth inhibition [55] . In some cell lines, this correlated with a delay in G2/M progression and a decrease in the inhibitory phosphorylation of Tyrosine 15 on cdc2 (another molecular marker of late G2 or early M).
These data suggest that s80 HER4 may engage aspects of the cell cycle machinery at this cell cycle stage. In support of this observation, the intracellular domain of ErbB4/ HER4 contains a functional D-Box sequence [56] . These motifs are found in cyclin B and other mitotic targets that are ubiquitylated by the anaphase promoting complex/ cyclosome (APC/C) and then destroyed by proteosomal degradation during mitosis. Mutation of the s80 HER4 D-Box sequence prolongs s80 HER4 protein half-life and amplifies its ability to produce a G2/M delay (Figs. 3 and 4) .
While expression of s80 HER4 decreased growth of mammary tumor cells in vivo, the expression of the Dbox mutant of s80 HER4 had a more profound effect on the inhibition of polyoma virus middle T-induced mouse breast cancer tumor growth, presumably due to its increased stability [56] (Fig. 5) .
This supports the idea that s80 HER4 may be a tumor suppressor protein, perhaps accessing the cell cycle machinery in some cells. These results further suggest that nuclear s80 HER4 destruction may be necessary for mitosis to proceed, and that targeted destruction of nuclear s80 HER4 may represent one mechanism used by cancer cells to escape ErbB4-mediated growth inhibition.
Expression of ErbB4/HER4 at the Cell Membrane and in the Nucleus Correlates with Improved Prognosis in Patients with Breast Cancer
Loss of HER4/ErbB4 activity impairs lactogenic differentiation of the mammary epithelium. This observation is very intriguing in light of the studies demonstrating the protective effects of lactation and involution against tumor formation in the mammary epithelium, due perhaps to the terminal differentiation and clearing of a large population of mammary epithelial cells. Furthermore, the ability of ErbB4/HER4 to induce differentiation of the mammary epithelium may impact tumor grade, and therefore, patient outcome, since the presence of a more differentiated phenotype generally correlates with a more favorable prognosis in human breast cancers. Consistent with this idea, most studies agree that tumors expressing ErbB4/HER4 generally present with a more favorable prognosis [31] [32] [33] [34] . It is thus conceivable that ErbB4/HER4 and/or s80 HER4 may confer a decreased susceptibility to tumor formation or tumor progression, perhaps through growth inhibition or perhaps through enhanced differentiation, or both.
However, conflicting evidence has been reported, in which ErbB4/HER4 expression increases the growth of estrogen-responsive cancer cells in culture [77] [78] . Reminiscent of these cell culture studies, there are conflicting reports regarding the prognostic value of ErbB4/HER4 expression in human breast cancers. Some reports demonstrate that HER4/ErbB4 expression in the nucleus correlates with positive prognostic indicators (estrogen receptor expression, lower tumor grade, increased differentiation, lower proliferative index) and greater disease-free and overall survival [40] . However, contrasting reports describe decreased survival in subsets of women whose breast cancers express nuclear HER4/ERBB4 [37] . This observation must be clarified, however. This study indicates that HER4/ErbB4 expression correlates with a more positive prognosis compared to tumors that do not express HER4/ ErbB4. It is within this subset of tumors with a good prognosis that this distinction was made between tumors bearing nuclear HER4/ErbB4 and those bearing membrane/ cytoplasmic HER4/ErbB4 [34, 37] .
ErbB4/HER4 Cytoplasmic Isoforms, CYT1 and CYT2: Distinct Signaling Capabilities?
This discrepancy may stem from the different biological properties of the ErbB4/HER4 splice variants, of which there are four. The juxta-membrane isoforms, JMa and JMb, differ within the stalk region of the extracellular domain, with JMa harboring a TACE cleavage site, and JMb lacking this TACE cleavage site [43, 44] . Splice variations within the cytoplasmic domain generate the Cyt1 and Cyt2 isoforms. Cyt1 contains a 16-amino acid sequence absent in Cyt2 [45, 46] . This stretch of amino acids contains putative binding sites for PI3-kinase [45] and WW domain-containing proteins [78, 79] . Much of the work describing growth inhibition and differentiation in response to ErbB4/HER4 signaling was done with the JMaCyt1 isoform [42, 52, 55, 56] . Similarly, growth inhibition and lactogenic differentiation in response to s80 HER4 signaling has been studied primarily with the Cyt1 variant of s80 HER4 [52, 55, 56] . In contrast, the JMa-Cyt2 isoform of ErbB4/HER4 was shown to enhance cell viability of 32D cells, while the JMa-Cyt1 did not [81] . Note that both HER4-Cyt1 and HER4-Cyt2 have been previously detected in normal human mammary tissue as well as in many clinical breast cancer specimens and human breast cancer cell lines [37] .
There are at least two signaling motifs within the 16 amino acids that are specific to the Cyt1 isoform, and absent from the Cyt2 isoform, including a tyrosine, that when phosphorylated, yields an SH2-binding site for the p85 subunit of PI3 kinase [45] . The second potential signaling motif is a proline-rich region, PPPAY, which binds WW domain-containing proteins [79] Because HER4-Cyt2 lacks the 16 amino acid insert, it lacks this potential binding site for PI3-kinase and WW-domain proteins. Several WW domain-containing proteins have been shown to interact with s80 HER4 , including Wwox, a known tumor suppressor protein that shuttles between the nucleus and cytoplasm (like s80 HER4 ), and is reported to be absent at the genomic level in many breast cancers [79, 82] . However, there are two PPPxY motifs outside of the Cyt1 specific motif PPPAY that mediate interactions between Wwox and HER4-Cyt1 or HER4-Cyt2. YAP is another WW domain-containing protein that interacts with ErbB4/ HER4 [83] , but unlike with Wwox, displayed stronger binding to the Cyt1 than to the Cyt2 isoform of ErbB4/ HER4 (Shumang Feng et. al. preliminary data).
Recent studies suggest that HER4-Cyt2 exhibits greater stability as compared to HER4-Cyt1 [84] . Our preliminary studies suggest that the WW domain containing E3 ubiquitin ligase known as WWP1 interacts with HER4-Cyt1 preferentially to HER4-Cyt2, and directs the degradation of HER4-Cyt1 (Feng et. al., preliminary data) . Given that E3 ubiquitin ligases often target proteins for proteosomal degradation, this may explain why HER4-Cyt2 exhibits greater stability that HER4-Cyt1. Although the role of PI3 kinase, WWP1, YAP, or Wwox in s80 HER4 -mediated growth control is currently unknown, data from our lab and others indicate that the 16-amino acid Cyt1 domain engages signaling pathways to decrease growth of mammary epithelial cells. The destruction of this powerful signaling agent, HER4/ErbB4 and its products s80 HER4 and m80 HER4 and may involve a series of processes and different ubiquitination systems depending on their location in the cell. For example HER4/ErbB4 appears to be subject to degradation by several WW domain containing E3 ligases (Itch and WWP1) [80] and nuclear s80 HER4 is tagged for ubiquitin dependent degradation by the anaphase promoting complex [56] .
Conclusions Regarding HER4/ERBB4 and Future Directions
Despite years of study, mechanistic insights into the action of EGFR/ErbB family members are still being made. Activation at the cell surface targets multiple signaling cascades in the cytoplasm that transmit signals into the nucleus. In addition to this classic model of RTK signaling, recent reports demonstrate that each member of the ErbB family can traffic to the nucleus, opening the possibility that each receptor may have direct nuclear substrates. However, while nuclear localization of the first three members of the receptor family appears to involve full length receptor by translocation mechanisms not yet defined, the release of s80 HER4 , its nuclear localization and export sequences, its role in STAT5a nuclear action, its metabolism by D Boxdependent, APC/C-mediated ubiquitination and its localization in neural transcription complexes, all clearly indicate a nuclear role for this unique transmembrane tyrosine kinase. The molecular pathways accessed by ErbB4/HER4 db percentage of PCNApositive cells was the lowest of all groups (9.0±2.2) and was also significantly decreased when compared with HC11P-s80 (P<0.037).
achieve growth inhibition and differentiation of mammary epithelial cells and strongly support a growth inhibitory/ differentiation role for ErbB4/HER4 in the breast.
